Nuclear Medicine Market Forecast [2022-2028] | Reach USD 19.47 Billion; Fortune Business Insights™
29 août 2022 05h12 HE
|
Fortune Business Insights
Pune, India, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The nuclear medicine market size was USD 5.04 billion in 2020. The market is studious to grow from USD 5.57 billion in 2021 to USD 19.47 billion by...
Radiopharmaceuticals Global Market Report 2022: Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
23 août 2022 06h13 HE
|
Research and Markets
Dublin, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Prostate Cancer Nuclear Medicine Diagnostics Market to Hit $1,315.66 million by 2028 at 10.6% CAGR - Says, The Insight Partners
25 juil. 2022 10h30 HE
|
The Insight Partners
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global...
Global Oncology Partnering 2017-2022: Featuring Key Players AG Mednet, 3B Pharmaceuticals, Abbisko Therapeutics and Others
29 juin 2022 07h58 HE
|
Research and Markets
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Oncology Partnering 2017-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global...
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
27 juin 2022 01h00 HE
|
Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
Nuclear Medicine Market Size Worth USD 13 Billion by 2027 at 13% CAGR - Report by Market Research Future (MRFR)
20 juin 2022 08h08 HE
|
Market Research Future
New York, USA, June 20, 2022 (GLOBE NEWSWIRE) -- Nuclear Medicine Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Nuclear Medicine Market...
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
12 mai 2022 01h05 HE
|
Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
03 mai 2022 01h05 HE
|
Curium
ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized...
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
19 avr. 2022 01h00 HE
|
Curium
ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now...
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
05 avr. 2022 01h05 HE
|
Curium
ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug...